Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records Databases
NCT07225790 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3883
Last updated 2026-05-12
Summary
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions
Interventions
- DRUG
-
Initiation of abemaciclib plus letrozole/anastrozole
Any doses and frequency observed in clinical practice will be allowed
- DRUG
-
Initiation of letrozole/anastrozole
Any doses and frequency observed in clinical practice will be allowed
Sponsors & Collaborators
-
Food and Drug Administration (FDA)
collaborator FED -
Brigham and Women's Hospital
lead OTHER
Principal Investigators
-
Shirley Wang, PhD, ScM · Brigham and Women's Hospital
-
Denys Shay, MD · Brigham and Women's Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-11-03
- Primary Completion
- 2026-01-31
- Completion
- 2026-01-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926 ·Status: RECRUITING ·Phase: PHASE3
-
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
NCT05826964 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
NCT06179303 ·Status: RECRUITING ·Phase: PHASE2
-
CARE Initiative: Real-world Emulation of the PALOMA-2 Trial
NCT06607601 ·Status: COMPLETED
-
A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients
NCT00001384 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Women With Stage III Breast Cancer
NCT00002696 ·Status: SUSPENDED ·Phase: PHASE3
-
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
NCT01720602 ·Status: COMPLETED ·Phase: NA
-
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
NCT00005970 ·Status: COMPLETED ·Phase: PHASE3
-
Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment
NCT01564056 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
NCT02101385 ·Status: COMPLETED ·Phase: PHASE2
-
Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery
NCT00305825 ·Status: COMPLETED ·Phase: PHASE2
-
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
NCT01723774 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
NCT00270894 ·Status: COMPLETED ·Phase: PHASE2
-
High-dose Chemotherapy With Hematopoietic Stem-cell Rescue for High-risk Breast Cancer: Long-term Follow-up
NCT03087409 ·Status: COMPLETED
-
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
NCT00193206 ·Status: COMPLETED ·Phase: PHASE2
-
Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer
NCT00365365 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Women With Resected Breast Cancer
NCT00033683 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
NCT02789657 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery
NCT00039546 ·Status: UNKNOWN ·Phase: PHASE3
-
Combination Chemotherapy in Treating Women With Breast Cancer
NCT00003519 ·Status: COMPLETED ·Phase: PHASE3
-
Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy
NCT03281902 ·Status: ACTIVE_NOT_RECRUITING
-
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
NCT00087178 ·Status: COMPLETED ·Phase: PHASE3
-
Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer
NCT00436709 ·Status: UNKNOWN ·Phase: NA
-
Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
NCT03628066 ·Status: COMPLETED ·Phase: PHASE2
-
Nurse AMIE for Echo Show: Randomized Control Trial
NCT04673019 ·Status: COMPLETED ·Phase: NA